ICER shows where IRA could be heading

All of the companies with products CMS has selected for the first round of Medicare drug price negotiations have scrambled to meet an Oct. 2 deadline for submitting dossiers — and they don’t know what’s going to happen next. There is no playbook for how CMS will use their data to set prices. In a report released Monday, ICER has provided a roadmap that shows one way CMS might evaluate two of the drugs, Eliquis and Xarelto. In the process, ICER has shed light on methodology the agency could use more broadly to implement the IRA’s drug pricing provisions.

The Institute for Clinical and Economic Review report makes it clear that setting prices under the Inflation Reduction Act will be a complex, contentious exercise. ...